Swiss drugmaker Roche has stopped giving patients its experimental diabetes treatment taspoglutide in late stage clinical trials due to a high rate of adverse reactions, marking a major blow to drug once seen to have $2 billion a year potential. The decision was based on a higher-than-expected rate of discontinuations due to gastrointestinal (GI) intolerability...
Category: Research
Until this year, the glycated hemoglobin or hemoglobin A1c (HbA1c) test was used only for monitoring patients once they had been diagnosed with diabetes. In January 2010, however, the American Diabetes Association Standards of Medical Care in Diabetes added the measure of HbA1c 6.5% as a criterion for the diagnosis of diabetes, in addition to the fasting glucose test...
By zeroing in on several gene variations that are key markers of diabetes, Buckner and her team have been able to trace the path of autoimmune dysfunction...
A new study by University of Pittsburgh researchers has found that women who exclusively breastfeed their children for at least one month are less likely to develop type 2 diabetes.
The researchers studied the records of 2233 women, including 1828 mothers of which 56% breastfed their children for at least one month...
Improved standards of living and hygiene may be contributing to the rising rate of type 1 diabetes.
Researchers from the Washington State Department of Health trying to explain the continuous rise in incidents of type 1 diabetes studied records of children younger than 19 years hospitalizedfor type 1 diabetes in Washington State...
Researchers led by Columbia University Medical Center have discovered that the skeleton plays an important role in regulating blood sugar and have further illuminated how bone controls this process. The finding, published in Cell, is important because it may lead to more targeted drugs for type 2 diabetes...
University of Florida researchers have found that the variety of bacteria in a child’s digestive tract is strongly linked to whether that child develops type 1 diabetes. The connection could eventually give doctors an early test for the condition and a new way to treat the disease that afflicts more than 3 million Americans...
DiaMedica Inc., a Canadian biopharmaceutical company focused on developing novel treatments for diabetes and neurological disorders, announced the initiation of a type 1 diabetes program following the acquisition of Sanomune. The initiation of this program is based on encouraging preclinical results with DM-99, a naturally occurring protein that the company has previously...
Sanofi-aventis and the Juvenile Diabetes Research Foundation (JDRF) announced a unique partnership to develop therapeutic treatments for people with type 1 diabetes at different stages of the disease - both those living with the disease and the newly diagnosed - as well as preventing diabetes in those at risk...
Neurocrine Biosciences and Boehringer Ingelheim to Jointly Research and Develop Type 2 Diabetes Drug
Neurocrine Biosciences, Inc. announcedthat they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of type 2 diabetes. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is...